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It has been shown that sexual hormones have
an opposite effect on hepatic fibrosis progres-
sion and hepatocellular carcinoma develop-
ment. Sex differences among 2,762 chronic
HBsAg carriers consecutively referring Italian
hospitals in 2001 and in 2007 have been
evaluated, particularly focusing on the role of
gender on severity of liver disease. The over-
all sex ratio (males/females) was 2.6. Females
were more likely born abroad and new diag-
nosis cases; but less likely HIV coinfected. No
sex difference was observed regarding coin-
fection with other hepatitis viruses. The sex
ratio linearly increased with increasing se-
verity of liver disease, being 1.3 in normal
ALT, 2.8 in chronic hepatitis, 3.6 in liver
cirrhosis, and 6.8 in hepatocellular carcinoma.
Adjustment by multiple logistic regression
analysis for the confounding effect of age,
alcohol intake, HDV infection, HCV infection,
and BMI shows that male gender is an
independent predictor of the likelihood of
more severe liver disease (O.R. 1.7; C.I.
95%¼ 1.3–2.1). HBV-DNA levels resulted not
associated with the outcome of chronic HBV
infection. Despite some potential risk factors
associated with liver disease, such as HBV
genotype or mutations, not having been con-
trolled for due to lack of availability, the
observed sex disparity in the outcome of
chronic HBV infection may support biological
obervation that HBV infection could be con-
sidered a sex hormone–responsive virus.
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INTRODUCTION
Since several years, it is well known that men are
more likely than women to be chronic carriers of
Hepatitis B virus (HBV) [Blumberg et al., 1972]. This
difference may be due either to the more frequent
exposure to HBV in males, either to more likely HBV
clearance, once infected, in females, either to both
reasons.
Chronic hepatitis B virus infection appears to
progress more rapidly in males than in females
[McMahon et al., 1990; Chen 1993; Poynard et al.,
2001]. The relative risk of chronic HBV-related end-
stage liver disease, hepatocellular carcinoma (HCC),
and liver disease-related death are consistently sev-
eral fold (range from 1.5 to 7.6 times) higher in males
than in females [Lee et al., 1999; Evans et al., 2002;
Chang et al., 2000; Taylor et al., 2009].
In the last few years, we have conducted two surveys
on the characteristics of chronic hepatitis B surface
antigen (HBsAg) carriers referring Italian hospitals
[Sagnelli et al., 2008; Stroffolini et al., 2009]. It allows
us a good opportunity to evaluate sex differences in
chronic HBsAg carriers. Particular attention was
addressed to evaluate the potential independent role, if
any, of male sex in liver disease severity.
PATIENTS AND METHODS
The two studies have been previously described
[Sagnelli et al., 2008; Stroffolini et al., 2009]. Briefly,
the first study enrolled 1,366 chronic HBsAg carriers
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consecutively referring to 79 Italian hospitals (both
tertiary and peripheral centers) from 1 February
through July 31, 2001 [Sagnelli et al., 2008]. Hospi-
tals were randomly selected from all Italian hospitals
by a systematic cluster-sampling procedure. The
second study, performed in 21 tertiary hospitals,
recruited 1,396 HBsAg positive subjects consecutively
observed from September 2006 to February 2007
[Stroffolini et al., 2009]. In both studies, subjects as
either in-patients or out-patients represented the
target population. “Incident cases” were defined those
who were first diagnosed during the study period and
had a negative anti-HBc IgM test. “Prevalent cases”
were defined those observed during the study period
but known to be HBsAg positive. For each subject,
the demographic, clinical, and etiological data were
recorded using a pre-coded questionnaire.
Hepatitis B serum markers (HBsAg, HBeAg, anti-
HBe) and anti-HDV antibodies were determined by
commercial immunoenzyme assays (Abbott Laborato-
ries, North Chicago, IL). Antibodies to hepatitis C
virus (anti-HCV) were detected by third-generation
commercial immunoenzymatic assays (Ortho Diag-
nostic Systems, Raritan, NJ). Serum HBV DNA levels
were assessed by polymerase chain reaction (PCR)
amplification using different commercial assays avail-
able in 2007 (Cobas Ampliscreen HBV test, Roche;
Procleix Ultrio assay, Chiron), with low detection
limits of 600 copies/ml. HBV-DNA levels were only
measured for the 2007 cohort.
Chronic hepatitis was diagnosed by liver histology
or, for patients without liver biopsy, based on the
presence of persistently (>6 months) abnormal ala-
nine aminotransferase (ALT) values in the absence of
clinical, biochemical, and ultrasound markers of liver
cirrhosis [Gaiani et al., 1997]. Cirrhosis was diag-
nosed by either liver biopsy or the presence of
unequivocal clinical, biochemical, and ultrasound
signs. Hepatocellular carcinoma (HCC) diagnosis was
made by histology, imaging techniques or by a1-feto
protein value greater than 400ng/ml [Bruix and
Sherman, 2005].
Statistical Analysis
Continuous variables were summarized as means
and standard deviation, and categorical variables
were summarized as absolute and relative frequen-
cies. Differences in the means were evaluated on
unpaired Student’s t-test, and the Chi-squared test
was applied to categorical variables. A P value <0.05
was considered to be significant.
The crude odds ratios (O.R.), which are estimates
of the relative risk linking severity of liver disease
(i.e., liver cirrhosis and/or HCC) to potential risk
factors, were calculated by univariate analysis. Ad-
justed O.R. were calculated by stepway multiple
logistic regression analysis to identify variables that
were independently associated with severity of liver
disease. Only variables that resulted associated at
univariate analysis were entered into the logistic
model. In the logistic model, more severe liver disease
was the outcome variable; age, sex, anti-delta positiv-
ity, anti-HCV positivity, alcohol intake, and body
mass index resulted the independent variables. Ad-
justment for other potential confounding variables
such as diabetes, HBV genotype, or presence of HBV
genomic mutations was not performed, as these data
were not available.
RESULTS
Overall 2,762 chronic HBsAg carriers have been
evaluated. Comparison of the main characteristics of
subjects enrolled in the two studies is shown in
Table I. Mean age and sex distribution were quite
similar. Incident cases were more likely represented
in 2001, while people born abroad were more likely
recruited in 2007. The proportion of subjects HBeAg
positive and that of people coinfected with HDV or
HIV, was stable over time. The proportion of HBsAg
positive cases tested for anti-HDV was very high,
being 100% (1,366/1,366) in 2001 and 84.4% (1,179/
1,396) in 2007. The proportion of people HCV co-
infected strongly decreased over time from 16.3% in
2001 to 6.5% in 2007 (P< 0.01).
Table II reports the comparison by gender of the
combined two studies according to different variables.
The overall sex ratio was 2.6 (2,000 males/762
females). Females were more likely than males
incident cases (16.7% vs. 10.9%, P< 0.01) and born
abroad (7.9% vs. 5.1%, P< 0.04); but less likely HIV
coinfected (0.3% vs. 2.9%, P< 0.01). A significant
greater proportion (P< 0.01) of males had a more
severe liver disease (i.e., liver cirrhosis and/or HCC).
The sex ratio (M/F ratio) linearly increased according
to the severity of liver disease, being 1.3 in subjects
with normal ALT, 2.8 in those with chronic hepatitis,
3.6 in liver cirrhosis cases and 6.8 in those with
HCC.
Table III reports the crude and the adjusted O.R.
derived by multiple logistic regression analysis. At
univariate analysis (crude O.R.) all the variables
considered resulted associated with more severe liver
diseases, but not highest HBV-DNA levels (O.R. 0.74;
C.I. 95%¼ 0.56–1.00). After adjustment by multiple
logistic regression analysis for the disturbing influ-
ence of the other variables considered, male sex (O.R.
1.67; C.I. 95%¼ 1.34–2.06) resulted an independent
predictor of the likelihood of liver cirrhosis and/or
HCC (other than age, HCV and HDV infection, and
alcohol intake). Body mass index was not associated.
Comparison of male HBsAg positive carriers 6 years
apart shows that the mean age of subjects (48.7 years
vs. 49.9 years; P< 0.04), the proportion of people born
abroad (3.5% vs. 6.5%; P< 0.05), and the proportion
of liver cirrhosis cases (19.7% vs. 22.27%; P< 0.05)
significantly increased over time; while the propor-
tion of incident cases (13.8% vs. 8.4%; P< 0.01), and
that of people HCV coinfected (17.2% vs. 7.2%;
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P< 0.01) significantly decreased. No difference was
observed in the proportion of HBeAg positive cases
(11.7% vs. 11.6%), anti-HDV positivity (8.0% vs.
7.0%) and HIV positivity (3.1% vs. 2.6%). (Data not
shown).
Comparision of HBsAg positive female carriers
6 years apart evidences that the proportion of people
born abroad (5.9% vs. 10.0%; P< 0.01), and that of
people HDV coinfected (6.6% vs. 11.7%; P< 0.01)
nearly doubled over time; while the proportion of
incident cases (20.8% vs. 12.4%; P<0.01), and that of
people HCV coinfected (14.1% vs. 4.9%; P<0.01)
strongly decreased. The mean age of subjects (50.4
years vs. 49.0 years), the proportion of HBeAg
positivity (12.8% vs. 9.8%), that of HIV coinfected
(0.3% vs. 0.4%), and that of subjects with liver
cirrhosis (14.6% vs. 16.2%) did not show significant
changes over time. (Data not shown).
DISCUSSION
Firstly, we would like to outline the decreasing
proportion over time of incident cases in both gen-
ders, which is a further proof for the declining
endemicity of HBV infection in Italy [Stroffolini
2005]. However, the higher proportion of incident
cases in females than in males reflects the very high
adherence to HBsAg screening for pregnant women
during the third trimester of pregnancy. In fact, it
has been recently shown that as many as 97.9% of
both Italian and foreign pregnant women undergo to
the screening [Spada et al., 2011].
The present study confirms previous observations
that there is a propensity for chronic HBV infection
as well as for more active liver disease in men
[McMahon et al., 1990; Chen 1993; Poynard et al.,
2001]. The greater progression of hepatic fibrosis and
HCC in men may be due, at least in part, to a low
production of estradiol, which is a potent endogenous
antioxidant which suppresses hepatic fibrosis in
animal models, and attenuates reduction of redox
sensitive transcripion factors, hepatocyte apoptosis,
and HSC activation by inhibiting a generation of
reactive oxygen species in primary cultures [Shimizu
et al., 2007]. Further study recently confirmed the
protective role for estrogens against the development
of HCC in female subjects [Wang et al., 2012].
Androgen, in contrast to estrogen, exerts an opposite
effect on HBV transcription and replication. It has
been shown that the androgen pathway can increase
the transcription of HBV through direct binding of
the androgen-responsive element sites in viral en-
hancer I, explaining a higher titer in male carriers
and an increased risk of HCC [Wang et al., 2009].
Thus, sexual hormones have an opposite effect on
liver carcinogenesis, in which androgen promotes
TABLE I. Comparison of Chronic HBsAg Carriers in Italy in Two Different Studies (2001 vs 2007)
Factor 2001 study (n¼1,366) 2007 study (n¼1,396) P value
Age (years) 49.1  13.9 49.7  12.8 N.S.
Gender male 975 (71.4%) 1026 (73.5%) N.S.
Incident cases 200 (15.8%) 132 (9.5%) <0.01
Born abroad 57 (4.2%) 104 (7.4%) <0.01
HBeAgþ 164 (12.0%) 148/1,350 (11.0%) N.S.
Anti-HDVþ 104 (7.6%) 95/1,179 (8,1%) N.S.
Anti-HCVþ 223 (16.3%) 83/1,277 (6.5%) <0.01
Anti-HIVþ 31 (2.3%) 18/889 (2.0%) N.S.
HDV: Hepatitis D virus; HCV: Hepatitis C virus; HIV Human Immunodeficiency virus.
TABLE II. Comparison of Chronic HBsAg Carriers by Gender
Factor Males (n¼ 2,000) Females (n¼ 762) P value
Age (mean  SD) 49.3  13.1 49.7  14 N.S.
Incident cases 210/1,923 (10.9%) 123/737 (16.6%) <0.001
Born abroad 101/1,991 (5.1%) 60/758 (7.9%) 0.03
HBeAgþ 229/1,966 (11.6%) 83 (11.1%) N.S.
Anti-HDVþ 139/1,851 (7.5%) 60/694 (8.6%) N.S.
Anti-HCVþ 235/1,911 (12.3%) 71/732 (9.7%) N.S.
Anti-HIVþ 47/1,629 (2.9%) 2/626 (0.3%) <0.001
HBV DNA
a,b
undetectable 286/876 (32.6%) 110/347 (31.7%) N.S.
Diagnostic categoryc 277 (13.9%) 207 (27.2%) <0.001
Normal ALT 1216 (60.8%) 426 (55.9%)
Chronic hepatitis 425 (21.2%) 117 (15.3%)
Liver cirrhosis 82 (4.1%) 12 (1.6%)
HCC
HCC: Hepatocellular Carcinoma; HDV: Hepatitis D virus; HCV: Hepatitis C virus; HIV Human Immunodeficiency virus.
aOnly for 2007 study.
bOnly in untreated patients.
cThe sex ratio (M/F) was 1.3 in normal ALT, 2.8 in chronic hepatitis, 3.6 in liver cirrhosis and 6.8 in HCC.
J. Med. Virol. DOI 10.1002/jmv
Sex Differences in HBsAg Carriers in Italy 1901
tumors, but estrogen protects against tumors, by
regulating the HBV life cycle. HBV may be consid-
ered a sex hormone-responsive virus, which explains
the sex disparity in the outcomes of chronic HBV
infection.
According with the above-mentioned biological
studies, our epidemiological survey shows that the
male/female ratio was nearly fivefold higher in HCC
cases than in subjects with normal ALT (6.8 vs. 1.3).
This finding is in agreement with a previous Asian
study showing a greater incidence of HCC in HBsAg
positive men as compared to women, being the
cumulative lifetime HCC incidence 27.4% in men and
7.9% in women, respectively [Huang et al., 2011].
Moreover, the present study, controlling by multiple
logistic analysis for important risk factors associated
with liver disease, shows that gender alone is truly
responsible for the increasing ratios observed with
increasing severity of liver disease confirming the
relevance of molecular signaling studies.
Presence of coinfection with other viruses deserves
some comment. No gender difference was observed
regarding anti-HDV positivity. However, the propor-
tion of males Delta coinfected was stable over time,
but the corresponding figure for females increased
over time, suggesting a potential survival phenom-
enon (i.e., a greater proportion of males than females
more likely died for liver diseases HDV related). The
very high proportion of HBsAg positive carriers
tested for HDV reflects the great attention and
awareness addressed to HDV infection in Italy.
No intergender difference was observed in the
proportion of subjects HCV coinfected. However, in
both genders, HCV infection significantly decreased
over time, confirming the vanishing trend of the
infection recently reported [Guadagnino et al., 2013].
Few subjects were anti-HIV coinfected, with a male
predominance stable over time, reflecting more likely
sources of exposure in male sex.
In conclusion, this survey evidences several differ-
ences in sex-related HBV chronic infection, with a
remarkable higher proportion of males with more
severe liver disease. We are aware that some risk
factors associated with liver disease, such as HBV
genotype or mutations, have not been controlled for
because not available. It represents a potential
limitation of the present study. However, the ob-
served sex disparity in the outcome of chronic HBsAg
carriers, even if derived from only an observational
study, may support biological observation that HBV
infection could be considered a sex-hormone respon-
sive virus.
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